Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman

Key Concepts

• Obesity Market: A significant and growing market estimated to be worth upwards of $130 billion when including diabetes.
• GLP-1 (Glucagon-like peptide-1): A class of drugs that mimic the effects of the GLP-1 hormone, used for weight loss and diabetes management.
• Amylin: A hormone that plays a role in glucose regulation and appetite control.
• Mersa: A potential acquisition target in the obesity drug market, offering a longer-acting GLP-1 (once a month) and an amylin option.
• Oral GLP-1 Pill: A pill form of GLP-1 medication, which, unlike injectable forms, does not require fasting before or after consumption.
• Risk Arbitrage: The practice of profiting from price discrepancies in related assets, often involving mergers and acquisitions.
• FTC Clearance: Approval from the Federal Trade Commission, necessary for mergers and acquisitions to proceed.
• TrumpCare RX: A proposed deal that would offer the lowest dose of weight-loss drugs for $149, in exchange for Medicaid and Medicare coverage for obesity treatment.
• Medicare Coverage: Government-funded health insurance for eligible individuals, crucial for expanding access to obesity treatments.
• Zepbound: A weight-loss drug developed by Eli Lilly.
• Novo Nordisk: A pharmaceutical company heavily invested in the obesity and diabetes market.
• Pfizer: A pharmaceutical company looking to expand its presence in the obesity market.
• Eli Lilly: A pharmaceutical company with a strong position in the obesity drug market.

The Battle for Obesity Market Dominance and the Significance of Mersa

The current landscape of the obesity market is characterized by intense competition and significant investment, with pharmaceutical giants like Novo Nordisk and Pfizer vying for dominance. Evan David Seager, Head of Healthcare Research at Beimo, highlights that the obesity market, when combined with diabetes, is projected to exceed $130 billion. This vast opportunity has made Mersa, a potential acquisition target, a focal point of this battle.

Mersa's Strategic Value

Mersa is considered highly valuable by both Novo Nordisk and Pfizer.

• For Novo Nordisk: Mersa represents a crucial opportunity to "make up ground" and support their "next leg of growth." The company has experienced a significant decline in its share price (slashed by more than half) due to issues with guidance and drug development. Mersa would provide Novo Nordisk with a longer-acting GLP-1, administered once a month, which is a key differentiator compared to their current once-a-week injectables. Furthermore, it offers another option for amylin, complementing their existing portfolio which includes "kagri krillide amin" and potentially the Mersa asset.
• For Pfizer: Acquiring Mersa would allow Pfizer to "make a big splash" and establish itself as a "significant third player" in the obesity space, a market where they currently have a limited presence.

Mersa's Unique Proposition: The Oral Peptide

A key feature of the Mersa asset is its nature as an oral peptide. This is significant because it "does not have the food effect" associated with other oral GLP-1 medications like Wegovy. Unlike Wegovy, which requires patients to avoid eating for 30 minutes after taking it, the Mersa oral pill eliminates this inconvenience, potentially improving patient adherence and convenience.

Valuation and Acquisition Dynamics

Despite the inherent risks associated with such acquisitions, Seager believes Mersa is "still relatively undervalued." He notes that a "de-risked obesity asset is hot" and that both Pfizer and Novo Nordisk, along with a third party mentioned in proxy filings, have shown interest. Seager anticipates that "the Pfizer bid to potentially best Novo Nordisk." A significant advantage for Pfizer is that they have already received FTC clearance for their bid, meaning the deal could close "within a number of weeks" if accepted.

Drug Pricing and Medicare Coverage: A Game Changer for Obesity Treatments

The discussion then shifts to the critical issue of drug pricing and the potential for expanded Medicare coverage for obesity treatments.

The Proposed TrumpCare RX Deal

A significant development is an expected deal, potentially announced as early as tomorrow, concerning the lowest dose of weight-loss drugs. Under this proposal, the lowest dose would be sold on "TrumpCare RX" for $149. In exchange, this would secure Medicaid and Medicare coverage for these drugs specifically for the "treatment of obesity," as opposed to their current coverage for type 2 diabetes.

Impact on the Obesity Market

Seager emphasizes the "very meaningful" impact of this development, stating that "that's been kind of the missing piece when it comes to the obesity market getting real Medicare coverage." While some patients currently access these drugs through a "backdoor via sleep apnea" for certain indications of drugs like Zepbound, this new deal would provide direct and widespread coverage.

Pricing and Concessions

The proposed price of $149 for the lowest dose on TrumpCare RX is considered a "pretty good deal." It is $50 lower than the lowest cash-pay price offered by Eli Lilly Direct. Seager anticipates that "the prices for the higher doses to be higher."

Net Benefit for Pharmaceutical Companies

Ultimately, Seager concludes that this development is a "win for Lily and Novo because they get access to this very large market." The expanded Medicare coverage is expected to significantly boost demand and revenue for these companies in the obesity treatment sector.

Conclusion: A Transformative Period for Obesity Therapeutics

The current period is marked by intense competition and strategic acquisitions in the burgeoning obesity market. Mersa's potential acquisition by either Pfizer or Novo Nordisk highlights the immense value of innovative obesity treatments. The proposed TrumpCare RX deal, offering expanded Medicare coverage for obesity drugs at a competitive price, represents a pivotal moment, poised to unlock the full potential of this multi-billion dollar market for pharmaceutical companies and improve access for millions of patients.